1915P The lenvatinib/pembrolizumab combination induces long lasting and complete responses in patients with metastatic anaplastic or poorly differentiated thyroid carcinoma: Results from a retrospective study and first results from the prospective phase II ATLEP trial - Dierks, C; Seufert, J; Ruf, J (Annals of Oncology, 2020)
et al.